A comparison of model-free phase I dose escalation designs for dual-agent combination therapies.

"The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the National Institute for Health Research (NIHR Advanced Fellowship, Dr Pavel Mozgunov, NIHR300576; and Prof Jaki’s Senior Research Fellowship, NIHR-SRF-2015-08-001) and by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care (DHSC). T Jaki and P Mozgunov received funding from UK Medical Research Council (MC_UU_00002/14)."